Tovecimig Plus Paclitaxel Improves Response and PFS in Biliary Cancer

The phase 2/3 COMPANION-002 trial randomized 168 patients with previously treated advanced biliary tract cancer to paclitaxel with or without tovecimig, a bispecific antibody targeting DLL4 and VEGF-A. The trial reported significantly improved objective response rate (18.0% vs 5.3%) and progression-free survival (4.7 vs 2.6 months) with the combination, though no overall survival difference was observed, and grade 3 or higher adverse events were more frequent with tovecimig plus paclitaxel (93.5% vs 64.2%).

Most relevant for: Patients with advanced biliary tract cancer who have progressed after one prior line of systemic therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.